PMCPA Case Library

1,752 PMCPA Rulings.
Every One Analysed.

The only structured, searchable PMCPA case library in the UK. Expert video walkthroughs, podcast episodes, and MCQ assessments on every ruling — so you understand why companies breach the Code, not just that they did.

▶ Video analysis per case
🎧 Podcast per case
✍ MCQ + CPD certificate
🔒 From £299/year
1752+
Case Studies
5 min
Per Video
5 pts
Per Case Passed
8
Themes
📚
Subscribe for full case library access
Read free summaries below, or subscribe to unlock expert video walkthroughs, podcast audio and CPD certificates.
Sign in See plans ↓
Free — Browsing
✓ Browse all 1752+ case titles
✓ Filter by theme & therapy area
✓ See case reference, company & outcome
✗ Search by company or clause
✗ Video walkthroughs
✗ Podcast episodes
✗ MCQ assessments & CPD certificates
Subscribed — Full Access
✓ Search by company, clause & case ref
✓ Expert video walkthrough per case
✓ Podcast episode per case
✓ MCQ quiz — 5 CPD points per pass
✓ Personalised CPD completion certificate
✓ New cases added monthly
Subscribe from £299/year →
Search by company, clause, case reference... 🔒
All (1752) Social Media & Digital (720) HCP Hospitality & Meetings (431) Data & Publications (321) Off-label Promotion (219) Patient Organisations (44) Transfers of Value (9) Promotional Material (4) Samples & Gifts (2)
Therapy Area: All areas Other (360) Oncology (218) Cardiovascular (189) Respiratory (178) CNS & Neurology (169) Infectious Diseases (115) Diabetes (114) Rare Diseases (104) Immunology & Rheumatology (84) Dermatology (67) Obesity & Weight Management (63) Musculoskeletal & Bone (60) Ophthalmology (31)
Showing 218 results · Oncology  · Clear
🔒 Subscribers only
AUTH/3803/07/23
Patient Organisations Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
GSK press release on dostarlimab
An anonymous complainant alleged GSK promoted Jemperli (dostarlimab) via a press release about an MHRA Early Access to Medicines Scheme (EAMS) positive scientific opinion for endometrial cancer.The…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3854/11/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
GSK
An anonymous health professional complained that a senior GSK employee had ‘liked’/reacted to a LinkedIn post about GSK drug data that was off-label.The post was created by an American medical …
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3806/8/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca breached ABPI Code over missing PI and weak PI signposting on Tagrisso HCP website pop-u
An anonymous (initially contactable) complainant, describing themselves as a current AstraZeneca employee, raised concerns about the UK HCP website “Tagrisso Connect” for Tagrisso (osimertinib)…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3825/9/23
HCP Hospitality & Meetings Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Janssen
BeiGene complained about a Janssen Europe (Janssen Pharmaceutica NV) industry symposium at EHA 2023 in Frankfurt (8 June 2023) titled “You have a new match! Pairing treatment and patients togethe…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3857/11/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca breached Clause 12 requirements in LinkedIn post promoting Calquence National Summit (AU
An anonymous, contactable health professional complained about an AstraZeneca sponsored LinkedIn post promoting a “CLL National Summit 2023”.The version relied on by the Panel (PMCPA screenshot…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3866/12/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Merck Serono
A health professional complained about frequent emails (said ~every 4 days) from a third-party medical publisher, paid for by Merck Serono, promoting Bavencio (avelumab).Emails used subject lines f…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3860/12/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Novartis
An anonymous UK doctor complained about a promotional email for Pluvicto sent by a third-party medical publisher on behalf of Novartis Global.The email’s sender/subject line did not make clear it…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3862/12/23
Off-label Promotion Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Gilead
An anonymous, contactable UK doctor complained about an email (27 Nov 2023) from a named medical publication with the subject “Genitourinary Cancers: ESMO 2023 Update”.The email looked like an …
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3861/12/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Novartis
A UK doctor received a third-party medical publisher email (21 Nov 2023) with the subject “ESMO 2023: Prostate Cancer Update”, implying an unbiased conference update.The email’s “Watch now�…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3869/12/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Eli Lilly
A complainant (a doctor) saw a paid “Sponsored” Facebook advertisement from a medical publisher titled “Treating High-Risk Early BC”, which also appeared repeatedly and later on Instagram. …
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3686/8/22
Off-label Promotion Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Eli Lilly
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3687/8/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
An ex-employee complained about UK employees’ engagement with a LinkedIn post authored by an AstraZeneca US employee about FDA approval in metastatic non-small cell lung cancer (NSCLC), linking t…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3707/11/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
A senior AstraZeneca employee working for the US affiliate posted on their personal LinkedIn about an FDA approval for a new treatment combination for Stage IV (metastatic) NSCLC, with an embedded …
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3720/12/22
Off-label Promotion Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Complainant v GSK
A health professional complained about a promotional email for BLENREP (belantamab mafodotin) sent on behalf of GlaxoSmithKline (GSK) on 27 December 2022.The email subject line was: “GSK: Rethink…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3710/11/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
MSD
A concerned health professional complained about a LinkedIn post (by a senior leader from NHS England) that was ‘liked’ by Merck Sharp & Dohme (MSD) staff based in the UK.The post followed …
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3690/8/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
GSK
A non-contactable complainant (described as a concerned health professional) complained about a UK-based senior medical GSK employee reacting “loves this” to a LinkedIn post from a renowned can…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3622/3/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
A physician complained about a Medscape rolling banner advertisement for Forxiga (dapagliflozin), marketed by AstraZeneca.The complainant provided screenshots of frames 2–4; AstraZeneca provided …
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3608/2/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
A contactable complainant (self-described medical oncologist) alleged AstraZeneca promoted its current and future oncology pipeline to the public via LinkedIn.The LinkedIn post was made by a named …
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3618/3/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca breached ABPI Code over Forxiga “start on 10mg” dosing claims hidden behind footnote (AU
An anonymous, contactable health professional complained about Forxiga (dapagliflozin) promotion by AstraZeneca. The complaint related to (1) a call with an AstraZeneca representative and (2) claim…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3631/4/22
HCP Hospitality & Meetings Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca & Daiichi Sankyo
A consultant medical oncologist complained about a virtual advisory board held on 7 April 2022 titled “T-DXd in the second-line setting in HER2+ mBC”. The meeting concerned a proposed new (seco…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3639/4/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Roche Products Ltd – Polivy dosing webpage omitted key administration instructions (AUTH/3639/4/22)
An anonymous health professional complained about Roche’s Polivy (polatuzumab vedotin) promotional website, specifically the dosing page (GB-00004744; date of preparation September 2021).The comp…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3663/6/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Roche
An anonymous, contactable complainant (self-described health professional) alleged off-label promotion of Ocrevus (ocrelizumab) on Roche Products Ltd’s “Roche Resources” website.The complaint…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3667/6/22
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Roche
A health professional complained about a Roche Resources website page in the “Congresses and Meetings” section (“Future Positive Lite”; ref M-GB-00005336, date of preparation November 2021)…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3646/5/22
Off-label Promotion Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Roche
An anonymous health professional complained about Roche’s HCP-gated Roche Resources promotional webpage for Rozlytrek (entrectinib) focused on dosing considerations (material code M-GB-00004833; …
Clauses: NONE
2022 🔒 Subscribe
← Prev 1 2 3 4 5 Next → Page 2 of 10 — 218 cases
Unlock the Full Case Library
Annual subscription — instant access, cancel anytime.
🏆
The only PMCPA case library of its kind
No other provider publishes a structured, searchable library of PMCPA rulings with video and podcast. A single half-day compliance workshop from a specialist provider typically costs £499+ — for one session. Individual access here is £299 for a full year of 2,000+ cases.
PMCPA Case Library — Team (100 seats)
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
Enquire for bulk pricing →
Individual
For a single learner
£299
per year
Less than a single half-day workshop
  • 1 user seat
  • All 1752+ case studies
  • Video + podcast per case
  • MCQ quiz per case
  • 5 points per case passed
  • New cases added monthly
Create account or sign in to buy
Most Popular
Team 5
Up to 5 team members
£999
per year (£200/seat)
£200/person — the most cost-effective team option
  • 5 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • New cases added monthly
  • Admin management portal
Create account or sign in to buy
Team 25+
25+ team members
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
  • 25 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • Bulk seat management
  • Priority support
Enquire for bulk pricing →

Questions? Email [email protected]  ·  14-day money-back guarantee  ·  Annual subscription, auto-renews